Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandra M Swain

Showing results (101-110 of 210) with videos related to

Pageof 21
Sort By:
Future Oncology (London, England)|April 13, 2019
IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancerJavier Cortés, Fabrice André, Anthony Gonçalves, et al.
Investigational New Drugs|June 15, 2007
A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancerSheri K Dennison, Samuel A Jacobs, John W Wilson, et al.
Evidence-Based Complementary and Alternative Medicine : Ecam|November 29, 2013
NCCAM/NCI Phase 1 Study of Mistletoe Extract and Gemcitabine in Patients with Advanced Solid TumorsPatrick J Mansky, Dawn B Wallerstedt, Timothy S Sannes, et al.
Research Square|December 11, 2023
iGenSig-Rx: an integral genomic signature based white-box tool for modeling cancer therapeutic responses using multi-omics dataSanghoon Lee, Min Sun, Yiheng Hu, et al.
Breast Cancer Research and Treatment|November 25, 2011
Twenty-five year results of the national cancer institute randomized breast conservation trialNicole L Simone, Tu Dan, Joanna Shih, et al.
BMC Bioinformatics|June 19, 2024
iGenSig-Rx: an integral genomic signature based white-box tool for modeling cancer therapeutic responses using multi-omics dataSanghoon Lee, Min Sun, Yiheng Hu, et al.
Breast Cancer Research and Treatment|August 21, 2019
Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combinationSandra M Swain, Gong Tang, Peter C Lucas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2004
A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancerPeter F Lebowitz, Jennifer Eng-Wong, Sandra M Swain, et al.
Investigational New Drugs|August 26, 2006
Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancerNeelima Denduluri, James J Lee, Janice Walshe, et al.
Pharmacogenomics|September 24, 2020
Assessment of primary care practitioners' attitudes and interest in pharmacogenomic testingD Max Smith, Tarlan Namvar, Ryan P Brown, et al.
Pageof 21

Showing results (101-110 of 210) with videos related to

Sort By:
Pageof 21
Future Oncology (London, England)|April 13, 2019
IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancerJavier Cortés, Fabrice André, Anthony Gonçalves, et al.
Investigational New Drugs|June 15, 2007
A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancerSheri K Dennison, Samuel A Jacobs, John W Wilson, et al.
Evidence-Based Complementary and Alternative Medicine : Ecam|November 29, 2013
NCCAM/NCI Phase 1 Study of Mistletoe Extract and Gemcitabine in Patients with Advanced Solid TumorsPatrick J Mansky, Dawn B Wallerstedt, Timothy S Sannes, et al.
Research Square|December 11, 2023
iGenSig-Rx: an integral genomic signature based white-box tool for modeling cancer therapeutic responses using multi-omics dataSanghoon Lee, Min Sun, Yiheng Hu, et al.
Breast Cancer Research and Treatment|November 25, 2011
Twenty-five year results of the national cancer institute randomized breast conservation trialNicole L Simone, Tu Dan, Joanna Shih, et al.
BMC Bioinformatics|June 19, 2024
iGenSig-Rx: an integral genomic signature based white-box tool for modeling cancer therapeutic responses using multi-omics dataSanghoon Lee, Min Sun, Yiheng Hu, et al.
Breast Cancer Research and Treatment|August 21, 2019
Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combinationSandra M Swain, Gong Tang, Peter C Lucas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2004
A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancerPeter F Lebowitz, Jennifer Eng-Wong, Sandra M Swain, et al.
Investigational New Drugs|August 26, 2006
Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancerNeelima Denduluri, James J Lee, Janice Walshe, et al.
Pharmacogenomics|September 24, 2020
Assessment of primary care practitioners' attitudes and interest in pharmacogenomic testingD Max Smith, Tarlan Namvar, Ryan P Brown, et al.
Pageof 21